Eosinophilic Gastrointestinal Disorders in the Pediatric Population

Why It Matters

Rising EGID rates and clear genetic and environmental risk factors demand coordinated pediatric specialty care, making Seattle Children’s new program a critical resource for early diagnosis and treatment.

Key Takeaways

• Eosinophilic GI disorders are chronic immune-mediated, not allergic.
• Eosinophilic esophagitis accounts for 80‑90% of pediatric cases.
• Early antibiotic or PPI exposure markedly raises pediatric EGID risk.
• Strong genetic component; first‑degree relatives face up to 64‑fold risk.
• Seattle Children’s EGID program launched August 2025 to centralize care.

Summary

Dr. Pickkins, a pediatric gastroenterology professor at Seattle Children’s, presented an overview of eosinophilic gastrointestinal disorders (EGIDs) in children, highlighting the launch of a dedicated EGID program at the hospital in August 2025. He emphasized that EGIDs are chronic immune‑mediated inflammatory conditions, distinct from classic allergic diseases, and can affect any layer of the gastrointestinal tract, with eosinophilic esophagitis (EoE) comprising the majority of pediatric cases.

The talk detailed epidemiology, noting a prevalence of roughly 1 in 1,500 pediatric patients for EGIDs overall, and 34 per 100,000 for EoE. Incidence peaks between ages five and ten, while eosinophilic gastritis appears in younger children and eosinophilic colitis is rarer in pediatrics. Genetic predisposition is significant—first‑degree relatives face a 10‑ to 64‑fold increased risk, with several immune‑related genes implicated. Environmental factors such as early‑life antibiotic use and infant proton‑pump inhibitor therapy dramatically elevate risk, likely via gut microbiome disruption and altered barrier function.

Dr. Pickkins underscored the importance of thorough family histories, citing that a relative who required esophageal dilation raises a child’s risk by about 10%. He also referenced a Danish cohort study linking prenatal and infant antibiotic exposure to an 80% rise in EGID incidence, and a 16‑fold increase associated with infant PPI use, especially in preterm infants. The presentation highlighted regional variations in the United States—EoE is more common in the Northeast, whereas eosinophilic gastritis predominates in the South and Midwest—suggesting environmental allergen influences.

The expanding prevalence and complex risk profile underscore the need for specialized multidisciplinary care. Seattle Children’s new EGID program aims to streamline diagnosis, provide targeted therapies, and facilitate research, positioning the institution as a hub for managing a condition that is increasingly recognized worldwide and outpacing current diagnostic capacity.

Original Description

Watch this expert-led presentation to explore the pathophysiology and clinical spectrum of pediatric EGIDs, including current diagnostic criteria and evaluation strategies.